构筑全球竞争新优势 迪哲医药两款源头创新药物将公开最新研究进展

Core Insights - DIZHE Pharmaceutical announced the presentation of two innovative drugs, DZD8586 and DZD6008, at the 2025 ASCO annual meeting, focusing on their advancements in treating B-cell non-Hodgkin lymphoma (B-NHL) and non-small cell lung cancer (NSCLC) [1][2] Group 1: DZD8586 - DZD8586 is a first-in-class, non-covalent dual-target inhibitor of LYN/BTK that can fully penetrate the blood-brain barrier [1] - In a study involving 51 patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DZD8586 demonstrated an objective response rate (ORR) of 84.2% at a 50mg dosage, with 78.9% of patients continuing treatment [1] - Another study on DZD8586 for treating relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) showed good anti-tumor activity and safety at both 50mg and 75mg dosages [2] Group 2: DZD6008 - DZD6008 is a novel, highly selective EGFR tyrosine kinase inhibitor (TKI) that also fully penetrates the blood-brain barrier [2] - In a study of 12 advanced NSCLC patients with various EGFR mutation types, DZD6008 exhibited encouraging and durable anti-tumor activity with good tolerability [2] - The ongoing research aims to further validate the efficacy and safety of DZD6008 in a broader population, potentially enhancing treatment options for advanced lung cancer patients [2] Group 3: Company Strategy and Future Plans - The CEO of DIZHE Pharmaceutical expressed confidence in advancing DZD8586 to Phase III clinical trials, highlighting its significant efficacy in treating CLL/SLL [2] - The company aims to accelerate the global development of both DZD8586 and DZD6008, seeking to provide more treatment options for patients with B-NHL and NSCLC [2]